A Multicenter, Open-Label Safety and Efficacy Study of ADS-5102 Amantadine Extended Release Capsules in Patients With Multiple Sclerosis and Walking Impairment
Phase of Trial: Phase III
Latest Information Update: 10 Sep 2018
Price : $35 *
At a glance
- Drugs Amantadine (Primary)
- Indications Movement disorders; Multiple sclerosis
- Focus Adverse reactions
- Acronyms INROADS3
- Sponsors Adamas Pharmaceuticals
- 02 Aug 2018 According to the Adamas Pharmaceuticals media release, first patient has been enrolled in this study.
- 02 Aug 2018 Status changed from not yet recruiting to recruiting, according to the Adamas Pharmaceuticals media release.
- 21 Jun 2018 Status changed from planning to not yet recruiting.